Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by Lepu Biopharma Co., Ltd., now recruiting.
Overview
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin is a phase 2 interventional study registered as NCT07283835 by Lepu Biopharma Co., Ltd., with 16 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Cretostimogene Grenadenorepvec.
Similar pages
not linked directly; found by shared links- TrialA Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
Shares Lepu Biopharma and the tag pipeline.
- TrialA Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Shares Lepu Biopharma and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.